EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges

Jayastu Senapati iD, Tapan M Kadia iD, Naval G Daver iD, Courtney D DiNardo iD, Gautam Borthakur, Farhad Ravandi, Hagop M Kantarjian iD

Cancer · 2025-04 · 131 (7)

DOI: 10.1002/cncr.35806 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 19.03.2025. Verfasst von Jayastu Senapati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 193 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence, University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Focused research in acute myeloid leukemia (AML) biology and treatment has led to the identification of new therapeutic targets and several new drug approvals over the last decade. Progressive improvements in response and survival have mirrored these improvements in treatment options. Traditionally adverse subtypes such as FLT3 –internal tandem duplication–positive AML now have better outcomes with potent FLT3 inhibitors, and menin inhibitors in KMT2A ‐rearranged and other MEIS/HOX–dependent leukemias hold promise toward improving outcomes. More patients with AML are now able to undergo a consolidative allogeneic hematopoietic stem cell transplantation (HSCT), and the rates of nonrelapse mortality with or without HSCT have also decreased. Comprehensive genomic interrogation of AML has elucidated mechanisms of response and resistance to treatments, which has enabled more precise decision algorithms and better prognostication. Deep levels of measurable residual disease assessment in some AML subsets hold the potential to dynamically modify treatment on the basis of these responses. Improving frontline intensive and low‐intensity therapies, by incorporating venetoclax and other targeted agents, is the most important intervention to improve AML outcomes. Despite these developments, a sizeable percentage of AML, such as AML with TP53 or MECOM aberrations, postmyeloproliferative neoplasm AML, and so forth, remains as subsets without significant improvement in outcomes and no targeted options. Evolving strategies with natural killer cell–based approaches, novel antibody–drug conjugates, bispecific T‐cell engagers, and engineered chimeric antigen receptor T‐cell therapies are being evaluated, and may fill the therapeutic vacuum for some of the high‐risk AML subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic AgentsHumansHematopoietic Stem Cell TransplantationMolecular Targeted TherapyPrognosis

Stichwörter der Autor:innen

TP53acute myeloid leukemiaacute promyelocytic leukemiamenin inhibitorsvenetoclax

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Jayastu Senapati, Tapan M Kadia, Naval G Daver, Courtney D DiNardo, Hagop M Kantarjian

Förderung

  • University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Senapati, J., Kadia, T. M., Daver, N. G., DiNardo, C. D., Borthakur, G., Ravandi, F., & Kantarjian, H. M. (2025). Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges. Cancer, 131(7). https://doi.org/10.1002/cncr.35806

Vancouver

Senapati J, Kadia TM, Daver NG, DiNardo CD, Borthakur G, Ravandi F, et al. Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges. Cancer. 2025;131(7). doi:10.1002/cncr.35806

BibTeX
@article{Senapati2025,
  author = {Senapati, Jayastu and Kadia, Tapan M and Daver, Naval G and DiNardo, Courtney D and Borthakur, Gautam and Ravandi, Farhad and Kantarjian, Hagop M},
  title = {Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {7},
  doi = {10.1002/cncr.35806}
}
Kostenlos starten →